Acquisition by Dambkowski Carl of 124962 shares of Apogee Therapeutics, at 49.07 subject to Rule 16b-3
| 866677AE7 | 83.48 0.76 0.90% |
About 62% of 866677AE7's investor base is looking to short. The analysis of the overall prospects from investing in SUI 27 15 JUL 31 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 866677AE7's historical and current headlines, can help investors time the market. In addition, many technical investors use SUI 27 15 bond news signals to limit their universe of possible portfolio assets.
866677AE7 |
Filed transaction by Apogee Therapeutics, Common Officer: Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
SUI 27 15 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 866677AE7 bond to make a market-neutral strategy. Peer analysis of 866677AE7 could also be used in its relative valuation, which is a method of valuing 866677AE7 by comparing valuation metrics with similar companies.
Peers
866677AE7 Related Equities
| SMLR | Semler Scientific | 15.60 | ||||
| BYDDY | BYD Co | 3.05 | ||||
| RCMT | RCM Technologies | 1.14 | ||||
| RBCAA | Republic Bancorp | 1.03 | ||||
| FRCOF | Fast Retailing | 0.00 | ||||
| 00108WAF7 | 00108WAF7 | 0.00 | ||||
| TRT | Trio Tech | 1.43 | ||||
| 90331HPL1 | 90331HPL1 | 2.25 |
Other Information on Investing in 866677AE7 Bond
866677AE7 financial ratios help investors to determine whether 866677AE7 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 866677AE7 with respect to the benefits of owning 866677AE7 security.